Our proof-of-concept study suggests that triple agonism of the GLP-1, glucagon, and Y2 receptors using the GOP combination may possess advantages even over RYGB, hitherto considered the standard-of-care for treatment of obesity and diabetes, and further studies are planned to explore the doses and combinations to obtain optimal efficacies [59]. This evidence concerns the gene GLP1R and diabetes mellitus.